AMLX
Amylyx Pharmaceuticals, Inc.
Overview
Amylyx Pharmaceuticals, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.81B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0716 Q&A exchanges
- Q4 FY2025Earnings2026-03-0319 Q&A exchanges
- Q3 FY2025Earnings2025-11-0614 Q&A exchanges
- Q2 FY2025Earnings2025-08-0714 Q&A exchanges
- Q1 FY2025Earnings2025-05-1012 Q&A exchanges
- Q4 FY2024Earnings2025-03-046 Q&A exchanges
- Q3 FY2024Earnings2024-11-0916 Q&A exchanges
- Q2 FY2024Earnings2024-08-0911 Q&A exchanges
- Q1 FY2024Earnings2024-05-096 Q&A exchanges
- Q4 FY2023Earnings2024-02-2213 Q&A exchanges
- Q3 FY2023Earnings2023-11-1116 Q&A exchanges
- Q2 FY2023Earnings2023-08-1013 Q&A exchanges
- Q1 FY2023Earnings2023-05-117 Q&A exchanges
- Q4 FY2022Earnings2023-03-1314 Q&A exchanges
- Q3 FY2022Earnings2022-11-1314 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.36—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.36 | — | — | — | — | EODHD |
Source: EODHD. AMLX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AMLX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.72 | $1.37 | +25.4% | -2.7% | -3.9% |
| Q4 FY2026 | $1.72 | $1.41 | +22.0% | -3.5% | -5.3% |
| Q3 FY2026 | $1.89 | $1.59 | +19.1% | +1.8% | -1.0% |
| Q2 FY2026 | $2.05 | $1.53 | +33.7% | +1.0% | +2.4% |
| Q1 FY2025 | $2.01 | $1.58 | +27.3% | -3.7% | -6.0% |
| Q4 FY2025 | $1.73 | $1.38 | +25.6% | +2.5% | 0.0% |
| Q3 FY2025 | $1.93 | $1.59 | +21.4% | -5.0% | -3.2% |
| Q2 FY2025 | $1.97 | $1.48 | +33.1% | +5.4% | +5.9% |
| Q1 FY2024 | $1.96 | $1.48 | +32.6% | -1.6% | +1.4% |
| Q4 FY2024 | $2.19 | $1.73 | +26.8% | -3.6% | -0.7% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joshua B CohenCEO1 yr 3 mo9 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Justin B KleeCEO1 yr 3 mo15 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- James M FratesCFO1 yr 3 mo15 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Gina MazzarielloChief Legal Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Camille L BedrosianChief Medical Officer1 yr 3 mo10 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AMLX.
$ curl https://api.spokenalpha.com/v1/companies/AMLXFAQ
Frequently asked about AMLX
Where can I find Amylyx Pharmaceuticals, Inc.'s (AMLX) earnings call transcripts?
Spoken Alpha indexes AMLX's earnings call transcripts at https://spokenalpha.com/companies/AMLX. Each call links to attributed speakers and parsed analyst Q&A. Amylyx Pharmaceuticals, Inc.'s own investor relations page is at https://investors.amylyx.com/.
When was Amylyx Pharmaceuticals, Inc.'s most recent earnings call?
Amylyx Pharmaceuticals, Inc. (AMLX) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is AMLX in?
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).